Additional file 2: of Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis

Fisher’s exact tests for variables associated with spontaneous viral clearance among PWID. Provides the results of Fisher’s exact tests for variables associated with spontaneous viral clearance among the PWID samples. (PDF 7 kb

Additional file 1: of Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis

Search strategies by risk group. Provides the search strings used to locate literature across the electronic databases for both the PWID and HIV+ MSM risk groups. (PDF 6 kb

Additional file 2: of The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis

Search strategy for CINAHL (via EBSCO), Embase (via Ovid), PsycInfo (via Ovid), and PubMed (via Medline)

Additional file 1: of The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis

PRISMA-P 2015 Checklist

HIV and HSV-2 prevalence and associations by female/male and race/ethnicity among never-injecting drug users, New York City, 2005-2011.

<p>HIV and HSV-2 prevalence and associations by female/male and race/ethnicity among never-injecting drug users, New York City, 2005-2011.</p

Observed HIV prevalence, population attributable risk percentages, and adjusted HIV prevalence among never-injecting drug users, New York City, 2005–2011.

*<p>Adjustment removes the effect of increased susceptibility to HIV infection.</p><p>due to HSV-2 infection. Using formula: Adjusted prevalence  =  Observed.</p><p>prevalence (1 – PAR%).</p

Demographic and drug use characteristics and sexual risk behaviors among never-injecting drug users, New York City, 1995–99 and 2005–11.

*<p>significant difference by chi-square test.</p

Special Characteristics and Transition Types by Country.

<p>*From literature search.</p><p>**Persistence is operationally defined as less than a 30% decline in new IDU cases around the transition period or over the 3 year span after the peak in IDU cases.</p

HIV seroprevalence among never-injecting drug users, New York City, 1995–1999.

#<p>Significant difference by chi square test (comparing same row across time periods).</p>*<p>Significant difference by chi square test (largest subgroup compared to all others within time period).</p

HSV-2 seroprevalence by HIV seroprevalence and by gender among never-injecting drug users, New York City, 1995–1999 and 2005–2011.

*<p>Significant differences for males vs. females by chi-square test.</p>#<p>Significant differences for HIV seropositives vs. HIV seronegatives by chi-square test.</p